Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent will be obtained from parent(s) or other legally acceptable representative(s), and informed assent from patient (if age appropriate) will be obtained~2. Male or female children ages ≥3 months to \<18 years.~3. Hospitalized, receiving systemic antibiotic therapy for the treatment of a suspected or confirmed infection, and expected to require hospitalization until after the end of treatment (EOT) evaluations are completed.~4. If female and has reached menarche, or has reached Tanner stage 3 breast development (even if not having reached menarche), the patient is practicing appropriate birth control or is sexually abstinent.~5. Likely to survive the current illness or hospitalization.~6. Sufficient intravascular access (peripheral or central) to receive study drug.~Exclusion Criteria:~1. History of hypersensitivity reactions to carbapenems, cephalosporins, penicillin, other β-lactam antibiotics.~2. If female, currently pregnant or breast feeding or has a positive serum β-human chorionic gonadotropin (β-hCG) pregnancy test.~3. Receipt of a blood or blood component (e.g., red blood cells, fresh frozen plasma, platelets) transfusion during the 24-hour period before enrolment.~4. BMI outside the range (below the 5th percentile or above the 85th percentile) for height, age, and weight except for children \<2 years of age.~5. Babies born prior to 37 weeks gestation (cohort 4 only).

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- CAZ-AVI (Type: EXPERIMENTAL): This arm will include 4 cohorts. Patients will be stratified by age.

Based on this trial design, predict the completion outcome and termination type (if applicable).